{"gene":"CD83","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2001,"finding":"The extracellular Ig domain of CD83 (hCD83ext) binds a ligand expressed on both immature and mature dendritic cells; this binding is not homophilic (immature DCs do not express CD83 yet bind hCD83ext), and soluble hCD83ext inhibits DC maturation by downmodulating CD80 and CD83 expression, and inhibits DC-dependent allogeneic and peptide-specific T cell proliferation in a concentration-dependent manner in vitro.","method":"Recombinant protein expression of soluble extracellular domain; binding assays on immature and mature DCs; DC maturation assays; allogeneic and peptide-specific T cell proliferation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — recombinant protein reconstitution, binding assays, functional inhibition assays with multiple readouts, single lab","pmids":["11748282"],"is_preprint":false},{"year":2002,"finding":"CD83 expression by thymic epithelial and dendritic cells is required for CD4+ single-positive thymocyte development: CD83-/- mice show a specific block in CD4+ SP thymocyte generation resulting in 75-90% reduction in peripheral CD4+ T cells, predominantly naive. Wild-type thymocytes transferred into CD83-/- mice fail to develop into mature CD4+ T cells, while CD83-/- thymocytes develop normally in wild-type hosts, demonstrating the requirement is in the stromal/thymic environment.","method":"CD83-/- mouse model; adoptive transfer of thymocytes and bone marrow stem cells into CD83-/- vs. wild-type hosts; flow cytometric analysis of T cell subsets","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with defined cellular phenotype, reciprocal adoptive transfer epistasis, independently replicated by multiple subsequent studies","pmids":["11955430"],"is_preprint":false},{"year":2000,"finding":"CD83 mRNA is transported from the nucleus to the cytoplasm via a specific CRM1-dependent nuclear export pathway. Inhibition of the hypusine modification of eIF-5A (by GC7) prevents CD83 surface expression by blocking nucleocytoplasmic translocation of CD83 mRNA, and this also significantly inhibits DC-mediated T lymphocyte activation.","method":"Pharmacological inhibition of hypusine formation (GC7); analysis of CD83 mRNA nuclear export; DC-mediated T cell activation assays","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with defined target, mRNA transport readout, functional T cell assay; single lab, indirect mechanism","pmids":["10790432"],"is_preprint":false},{"year":2001,"finding":"CD83 is an adhesion receptor: a soluble CD83-Ig fusion protein binds peripheral blood monocytes and a subset of activated CD3+CD8+ T lymphocytes. Binding to the CD8+ T cell line HPB-ALL is neuraminidase-sensitive, implicating sialic acid modification of a 72-kDa counterreceptor. Full-length CD83 expressed by a transfected carcinoma line mediates CD83-dependent adhesion to HPB-ALL cells.","method":"CD83-Ig fusion protein binding assays; neuraminidase treatment; immunoprecipitation of 72-kDa counterreceptor; adhesion assays with CD83-transfected cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays, immunoprecipitation, neuraminidase-sensitive adhesion, single lab","pmids":["11238630"],"is_preprint":false},{"year":2001,"finding":"Soluble CD83 (sCD83) is released from membrane CD83-positive cells by shedding (not de novo synthesis during short-term culture) and is detectable in normal human sera. Both activated B cell lines and monocyte-derived DCs release sCD83 proportionally to their mCD83 expression level.","method":"sCD83-specific ELISA; Western blotting; inhibition of de novo protein synthesis; culture of B cell lines and monocyte-derived DCs","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ELISA and Western blot with protein synthesis inhibition to distinguish shedding from new synthesis; single lab, two complementary methods","pmids":["11431426"],"is_preprint":false},{"year":2005,"finding":"CD83 mRNA contains four alternative splice variants in unstimulated PBMCs; the smallest splice product can be efficiently translated into a soluble CD83 protein. Recombinant soluble CD83 from this variant strongly inhibits T cell proliferation in MLR. Stimulation with PHA, TNF-alpha, or LPS upregulates full-length CD83 transcript and downregulates two of the three smaller splice variants.","method":"RT-PCR identification of splice variants; recombinant protein expression; MLR T cell proliferation assay; stimulation with mitogens/cytokines","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — recombinant protein with functional assay, splice variant characterization; single lab","pmids":["15905506"],"is_preprint":false},{"year":2005,"finding":"CD83 forms dimers via an intermolecular disulfide bond at cysteine 129. Mutation of C129 to serine abolishes dimerization. The monomeric mutant inhibits CD83 surface upregulation during DC maturation and inhibits DC-mediated allogeneic T cell stimulation in vitro, indicating functional activity of the soluble form is retained as a monomer.","method":"Recombinant mutational analysis (C129S); biochemical analysis of dimerization; DC maturation assays; MLR allogeneic T cell stimulation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with mutagenesis, single lab, single study","pmids":["15721284"],"is_preprint":false},{"year":2006,"finding":"CD83 mRNA expression is post-transcriptionally regulated via a novel cis-acting structured RNA element in its coding region that binds HuR. HuR binding does not affect mRNA stability but is required for cytoplasmic accumulation of CD83 transcripts via the CRM1 nuclear export pathway. RNAi knockdown of HuR reduces CD83 expression; inhibition of CRM1 (leptomycin B) or overexpression of defective Nup214/CAN similarly diminishes cytoplasmic CD83 mRNA.","method":"RNA-binding assays; transient transfection with post-transcriptional regulatory element reporters; RNA interference; leptomycin B treatment; dominant-negative Nup214 overexpression; mRNA stability assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (RNAi, pharmacological inhibition, dominant-negative, RNA-binding assays, reporter assays) in single lab establishing HuR-CRM1 axis","pmids":["16484227"],"is_preprint":false},{"year":2006,"finding":"APRIL (ANP32B), a protein ligand of HuR, contributes to nuclear export and subsequent translation of CD83 mRNA. RNAi knockdown of APRIL reduces CD83 expression. Phosphorylation of APRIL at threonine 244 regulates its nuclear export and thereby modulates the nucleocytoplasmic translocation of CD83 mRNA. In contrast, pp32 (ANP32A) is dispensable for CD83 expression.","method":"RNA interference (RNAi); identification of NLS and NES of APRIL; phosphorylation mapping (T244); CD83 expression analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi with specific controls, mutagenesis of phosphorylation site, single lab","pmids":["17178712"],"is_preprint":false},{"year":2007,"finding":"CD83 knockdown by siRNA in monocyte-derived dendritic cells significantly diminishes DC-mediated T cell proliferation and alters cytokine expression during T cell priming, establishing CD83 as an enhancer of DC-mediated T cell stimulation. This was demonstrated without the use of viral infection or pharmacological inhibitors.","method":"siRNA knockdown of CD83 in immature monocyte-derived DCs; electroporation for delivery; allogeneic T cell proliferation assay; cytokine expression analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean siRNA knockdown with specific functional readouts (proliferation + cytokine), single lab","pmids":["17442926"],"is_preprint":false},{"year":2011,"finding":"The transmembrane domain of CD83 blocks IL-10-driven, MARCH1-mediated ubiquitination and degradation of MHC class II and CD86 in dendritic cells. Mice with an ENU-induced mutation eliminating the CD83 transmembrane region show reduced surface MHC class II and CD86, demonstrating that the CD83 TM domain enhances MHC class II and CD86 expression by opposing MARCH1-dependent turnover.","method":"ENU mutagenesis screen generating TM-domain CD83 mutant mice; analysis of MHC class II and CD86 surface expression; MARCH1-dependent ubiquitination assays; IL-10 treatment","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with defined molecular mechanism (MARCH1 ubiquitination pathway), multiple orthogonal readouts, confirmed in follow-up study (PMID 27503069)","pmids":["21220452"],"is_preprint":false},{"year":2016,"finding":"MARCH8 is the E3 ubiquitin ligase responsible for regulating surface MHC II in thymic epithelial cells (TECs). CD83 controls the ubiquitination of MHC II by MARCH8 in TECs: mice with the Cd83 anu/anu mutation (lacking functional CD83 TM domain) have impaired CD4+ T cell selection, and deletion of March8 in Cd83 anu/anu mice restores CD4+ T cell selection to normal levels, placing CD83 upstream of MARCH8-mediated MHC II regulation in TECs.","method":"March8-/- mice; Cd83 anu/anu mice; March8/Cd83 double-mutant mice; flow cytometric analysis of MHC II on cortical and medullary TECs; CD4+ T cell development and repertoire analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double KO rescue, clean cellular phenotype, orthogonal to PMID 21220452","pmids":["27503069"],"is_preprint":false},{"year":2009,"finding":"GRAIL, a transmembrane RING finger E3 ubiquitin ligase, ubiquitinates CD83 on lysine residues K168 and K183 (but not K192) in its cytoplasmic domain, leading to proteasomal degradation of CD83 on CD4+ T cells. GRAIL-mediated CD83 downregulation requires an intact extracellular protease-associated domain and an enzymatically active RING domain. GRAIL knockdown by RNAi elevates CD83 levels, and CD83 expression on CD4+ T cells contributes to T cell activation as a costimulatory molecule.","method":"Retroviral transduction of GRAIL; GRAIL domain mutants; ubiquitination assays identifying K168/K183; proteasome pathway analysis; RNAi knockdown of GRAIL; CD4+ T cell activation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro ubiquitination with specific lysine mutagenesis, domain mutagenesis, RNAi rescue, functional T cell activation readout; single lab with multiple orthogonal methods","pmids":["19542455"],"is_preprint":false},{"year":2003,"finding":"EBV latent membrane protein 1 (LMP1) induces CD83 expression in B cells via NF-κB signaling. LMP1-mediated activation of the CD83 promoter is dependent on NF-κB, as shown by luciferase reporter assays using the CD83 promoter and LMP1 signaling mutants. Fusion constructs of the LMP1 TM domain with intracellular signaling domains of CD40, TNF-R1, or TNF-R2 similarly transactivate the CD83 promoter via NF-κB.","method":"Luciferase reporter assays with CD83 promoter; LMP1 signaling mutants; inducible LMP1 expression system; NF-κB pathway analysis","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with multiple LMP1 mutants and chimeric constructs, NF-κB pathway confirmed; single lab","pmids":["12857898"],"is_preprint":false},{"year":2013,"finding":"The human CD83 promoter activity in DCs is regulated by a ternary transcriptional complex consisting of an upstream regulatory element, a minimal promoter, and an enhancer containing IRF- and NF-κB binding sites. IRF-1, IRF-2, IRF-5, p50, p65, and cRel regulate maturation-specific CD83 expression; mutation of any IRF-binding site causes significant loss of promoter activity, while NF-κB overexpression enhances transcription.","method":"ChIP-on-chip microarray; biocomputational analysis; luciferase reporter assays; EMSA; ChIP with specific TF antibodies; site-directed mutagenesis of IRF-binding sites; NF-κB overexpression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (ChIP, EMSA, reporter, mutagenesis) in single study with rigorous controls","pmids":["23339870"],"is_preprint":false},{"year":2007,"finding":"CD83 expression by thymic stromal cells influences MHC class II surface expression on B cells, DCs, thymic epithelial cells, and peritoneal macrophages: CD83-/- mice show 25-50% reduction in surface MHC class II on splenic B cells and DCs due to increased internalization of class II from the surface of CD83-/- B cells. MHC class II transcription, intracellular expression, heterodimer structure, antigen processing, and antigen presentation are normal.","method":"CD83-/- mice; flow cytometry for MHC class II surface and intracellular expression; MHC class II internalization assays; MHC class II transcription analysis; antigen processing/presentation assays","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with multiple readouts distinguishing surface vs. intracellular MHC II, internalization assay mechanistically informative; single lab","pmids":["17804692"],"is_preprint":false},{"year":2008,"finding":"CD83 expression on CD4+ T cells confers immunosuppressive function: retroviral transduction of CD83 into naive CD4+CD25- T cells induces a regulatory phenotype accompanied by Foxp3 induction. CD83+Foxp3+ T cells suppress the effector phase of contact hypersensitivity in vivo and prevent paralysis in experimental autoimmune encephalomyelitis (EAE), associated with suppression of IFN-gamma and IL-17 and increase in IL-10.","method":"Retroviral transduction of CD83 into naive CD4+ T cells; in vitro functional assays; adoptive transfer into contact hypersensitivity and EAE mouse models; cytokine analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — retroviral gain-of-function with in vivo functional readouts, multiple disease models; single lab","pmids":["18424708"],"is_preprint":false},{"year":2011,"finding":"CD83 inhibits T cell proliferation and cytokine (IL-2, IFN-γ) production via monocytes: CD83 stimulates monocytes to produce prostaglandin E2 (PGE2) via NF-κB-dependent upregulation of COX-2. COX-2-selective inhibitor NS-398 fully prevents CD83-triggered inhibition of T cell responses, and neither IL-10 nor TGF-β mediates this effect.","method":"T cell proliferation assays; cytokine measurement (IL-2, IFN-γ, PGE2); COX-2 inhibitor (NS-398); NF-κB activation analysis; depletion of monocytes; transwell assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple readouts, monocyte requirement demonstrated; single lab","pmids":["22065790"],"is_preprint":false},{"year":2017,"finding":"Soluble CD83 (sCD83) binds to myeloid differentiation factor-2 (MD-2), the co-receptor within the TLR4/MD-2 complex, on CD14+ monocytes. This binding rapidly degrades IRAK-1 and induces anti-inflammatory mediators IDO, IL-10, and PGE2 in a COX-2-dependent manner, leading to inhibition of T cell proliferation and IL-2 secretion and T cell unresponsiveness to further differentiation signals.","method":"Binding assays identifying MD-2 as sCD83 partner; IRAK-1 degradation assays; IDO/IL-10/PGE2 induction assays; COX-2 inhibition; T cell proliferation and cytokine assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding partner identification with functional pathway dissection, multiple downstream readouts; single lab","pmids":["28193829"],"is_preprint":false},{"year":2014,"finding":"CD83 engages in homotypic cell-cell contact interactions that inhibit pro-inflammatory DC responses. CD83 knockdown or cytoplasmic truncation abrogates the effects of homotypic binding. The inhibitory signal transduced by CD83 homotypic interaction operates via the MAPK pathway by inhibiting p38α phosphorylation. Conditional DC-specific CD83 KO mice develop exacerbated colitis, while mucosal CD83 overexpression protects against colitis.","method":"Conditional DC-specific CD83 KO mice; CD83 cytoplasmic truncation mutants; siRNA knockdown; colitis model (DSS); p38α phosphorylation assays; cell-cell contact assays; transwell controls","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO in vivo plus mechanistic pathway (p38 MAPK) with domain mutants; single lab","pmids":["25204675"],"is_preprint":false},{"year":2005,"finding":"CD83 protein localizes to the Golgi compartment and recycling endosomes in both immature and mature DCs. In immature DCs, CD83 cycles between endosomes and the cell surface; inhibition of endocytosis induces CD83 surface expression in immature DCs. During DC maturation, CD83 co-localizes with MHC class II in endocytic vesicles (exclusive to mature DCs), and the increase in surface CD83 results primarily from increased protein synthesis with contribution from regulated intracellular transport. Cathepsin inhibitors impair CD83 surface upregulation.","method":"Immunofluorescence co-localization with organelle markers; endocytosis inhibition; pulse-chase/protein synthesis analysis; cathepsin inhibitors; fractionation; live-cell imaging","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple localization methods with functional interventions (endocytosis inhibition, cathepsin inhibitors); single lab","pmids":["15746244"],"is_preprint":false},{"year":2015,"finding":"GRASP55 interacts with CD83 in human dendritic cells, binding via the C-terminal TELV-motif of CD83. Mutation of the TELV-motif disrupts GRASP55 binding, alters CD83 glycosylation pattern, and reduces CD83 membrane surface expression. GRASP55 interaction with CD83 is induced during DC maturation and plays a role in CD83 glycosylation and surface trafficking.","method":"Yeast two-hybrid screening; co-immunoprecipitation; TELV-motif mutagenesis; glycosylation analysis; co-localization studies; DC maturation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid + co-IP interaction identification, mutagenesis of binding motif with functional readout (glycosylation, surface expression); single lab","pmids":["25701785"],"is_preprint":false},{"year":2016,"finding":"B cell-intrinsic CD83 is required for normal MHC class II and CD86 upregulation and B cell proliferation after stimulation. In vivo, B cell-specific CD83 conditional KO causes a shift in germinal center dark zone/light zone composition, an enhanced IgE response, and a competitive disadvantage in GC responses in mixed bone marrow chimeras. CD83 B-cKO mice show impaired bacterial clearance of Borrelia burgdorferi with a shift toward Th2 responses.","method":"B cell-specific CD83 conditional KO mice (CD83 B-cKO); mixed bone marrow chimeras; immunization experiments; germinal center analysis; IgG/IgE measurements; Borrelia burgdorferi infection model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with multiple orthogonal in vivo readouts and cell-intrinsic mechanism confirmed by bone marrow chimeras","pmids":["26983787"],"is_preprint":false},{"year":2018,"finding":"Treg-intrinsic CD83 expression is essential for Treg differentiation upon activation. Treg-specific conditional CD83 KO mice show a pro-inflammatory phenotype, downregulation of Treg-specific differentiation markers, induction of an inflammatory profile, aggravated autoimmunity, and impaired resolution of inflammation.","method":"Treg-specific conditional CD83 KO mice; single-cell RNA-sequencing; flow cytometry for Treg markers; autoimmunity models; inflammatory resolution assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional cell-type-specific KO with defined phenotypic readouts, scRNA-seq; single lab","pmids":["29875316"],"is_preprint":false},{"year":2019,"finding":"DC-specific deletion of CD83 (CD83ΔDC) results in elevated IL-2 production, increased CD25 and OX40L expression on DCs, enhanced antigen-specific T cell responses, compromised Treg suppressive functions, and reduced peripheral Treg numbers. In bacterial infection models, CD83ΔDC mice clear Salmonella typhimurium and Listeria monocytogenes more efficiently with increased DC IL-12. In EAE, autoimmune inflammation is dramatically aggravated with increased CNS cell influx and Th17 numbers.","method":"DC-specific conditional CD83 KO (CD83ΔDC) mice; bacterial infection (Salmonella, Listeria); EAE model; cytokine profiling; T cell subset analysis; Treg functional assays","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional DC-specific KO with multiple orthogonal in vivo models and defined cellular mechanisms; single lab with comprehensive readouts","pmids":["31527313"],"is_preprint":false},{"year":2023,"finding":"CD83 in murine microglia restrains neuroinflammation: conditional deletion of CD83 in microglia results in an over-activated microglial state during EAE neuroinflammation, increased recruitment of pathogenic immune cells to the CNS, deterioration of resolving mechanisms, and exacerbated disease. CD83 expression is associated with pro-resolving microglial functions.","method":"Conditional CD83 KO in microglia; single-cell RNA-sequencing; EAE model; immune cell infiltration analysis; cytokine profiling","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with scRNA-seq and in vivo disease model; single lab","pmids":["37528070"],"is_preprint":false},{"year":2023,"finding":"CD83 functions as an immune checkpoint in macrophages: IL-4-stimulated alternatively activated macrophages express CD83, and conditional CD83 deletion in macrophages reduces inhibitory receptors (CD200R, MSR-1), decreases phagocytic capacity, reduces pSTAT-6 levels and Gata3 expression, increases pro-inflammatory mediators (TNF-α, IL-6, CXCL1, G-CSF), and enhances allo-reactive T cell stimulation with reduced Treg induction. In a wound healing model, CD83-deficient macrophages show increased inflammatory transcripts and altered tissue reconstitution.","method":"Conditional CD83 KO in macrophages (cKO); IL-4 stimulation; STAT-6 phosphorylation assays; cytokine measurement; phagocytosis assays; T cell proliferation assays; full-thickness excision wound healing model; gene expression analysis","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional cell-type-specific KO with multiple mechanistic readouts (STAT-6, receptor expression, functional assays); single lab","pmids":["36875129"],"is_preprint":false},{"year":2018,"finding":"Soluble CD83 alleviates experimental autoimmune uveitis (EAU) by inducing tolerogenic DCs through disruption of cytoskeletal (filamentous actin) rearrangements at the DC-T cell contact zone, leading to altered calcium microdomain localization and suppressed co-stimulatory molecule synaptic expression and calcium responses in DCs.","method":"EAU mouse model; flow cytometry; imaging studies of cytoskeletal rearrangements; calcium response assays in DCs; systemic and topical sCD83 application; co-stimulatory molecule expression analysis","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo disease model with mechanistic imaging and calcium signaling readouts; single lab","pmids":["30050530"],"is_preprint":false},{"year":2019,"finding":"Soluble CD83 enhances resolution of autoimmune antigen-induced arthritis via IDO induction: inhibition of IDO by 1-methyltryptophan completely abrogates sCD83 effects. TGF-β also mediates sCD83-induced reduction of bone destruction and cartilage damage. sCD83 reduces IL-17A, IFNγ, IL-6, TNFα, and RANKL expression, inhibits osteoclast differentiation, and increases regulatory T cell numbers in an IDO-TGF-β-dependent manner.","method":"Antigen-induced arthritis (AIA) mouse model; IDO inhibition (1-methyltryptophan); anti-TGF-β antibody blocking; cytokine quantification; osteoclast differentiation assays; Treg analysis","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with pharmacological pathway dissection (IDO inhibitor, TGF-β blockade), multiple mechanistic readouts; single lab","pmids":["31001257"],"is_preprint":false},{"year":2004,"finding":"CD38 engagement by agonistic anti-CD38 mAb on mature monocyte-derived DCs induces upregulation of CD83 expression and IL-12 secretion. Disruption of the CD38/CD31 interaction inhibits CD83 expression, IL-12 secretion, and MDDC-induced allogeneic T cell proliferation. CD38 is enzymatically active (cyclic ADP ribose synthesis) in mature DCs and its expression is NF-κB dependent.","method":"Anti-CD38 agonistic mAb stimulation; CD38/CD31 blocking; CD83 expression analysis; IL-12 secretion assays; T cell proliferation assays; NF-κB inhibition","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological/antibody manipulation with specific functional readouts; single lab","pmids":["15114667"],"is_preprint":false},{"year":2011,"finding":"Activated T cells induce rapid CD83 expression on B cells via CD40 engagement: in vivo T cell activation induces CD83 on ~80% of B cells in draining lymph nodes without requiring TCR/MHC binding (antigen-non-specific bystander effect). This induction requires cell contact and is blocked by anti-CD40L antibody, demonstrating CD40-dependent, contact-mediated CD83 induction on B cells.","method":"T cell receptor transgenic mice; cognate peptide injection; CD40L-blocking antibody; transwell separation assays; MHC-mismatched co-culture controls; flow cytometry","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro genetic/antibody-blocking with multiple controls establishing CD40-dependence; single lab","pmids":["21277328"],"is_preprint":false},{"year":2014,"finding":"Membrane CD83 on mature DCs enhances intracellular calcium release in T lymphocytes during DC-T cell interaction. siRNA knockdown of CD83 or antibody blocking of surface CD83 on mature DCs reduces both calcium signal amplitude and the proportion of responding T cells, and abrogates T cell signaling in the absence of extracellular calcium, indicating CD83 promotes calcium release from intracellular stores.","method":"siRNA knockdown; anti-CD83 mAb blocking; calcium indicator (Fluo-4-AM); flow cytometry; confocal microscopy; CFSE proliferation assay; calcium-free medium experiments","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and antibody blocking with calcium imaging by multiple methods; single lab","pmids":["24436459"],"is_preprint":false}],"current_model":"CD83 is a type I transmembrane immunoglobulin superfamily glycoprotein whose membrane-bound form on mature dendritic cells, thymic epithelial cells, activated B and T cells, macrophages, and microglia promotes MHC class II and CD86 surface expression by opposing MARCH1/MARCH8-mediated ubiquitination and degradation, regulates CD4+ T cell development in the thymus, modulates DC activation state via homotypic interactions through p38 MAPK inhibition, enhances T cell calcium signaling and co-stimulation, and controls B cell maturation and germinal center responses; its soluble form (generated by alternative splicing or shedding) binds the TLR4/MD-2 co-receptor on monocytes to induce IDO, IL-10, and PGE2 in an IRAK-1 degradation–COX-2–dependent manner that suppresses T cell proliferation, while CD83 mRNA export from nucleus to cytoplasm is regulated by a HuR/APRIL/CRM1-dependent pathway via a coding-region post-transcriptional regulatory element, and its protein is subject to ubiquitin-mediated proteasomal degradation by the E3 ligase GRAIL at cytoplasmic lysines K168/K183 and to glycosylation-dependent trafficking via interaction with GRASP55 through its C-terminal TELV motif."},"narrative":{"mechanistic_narrative":"CD83 is a type I transmembrane immunoglobulin-superfamily glycoprotein that acts as a central rheostat of antigen-presenting cell function and T cell tolerance, operating through both membrane-bound and soluble forms [PMID:21220452, PMID:28193829]. Its membrane-bound form stabilizes surface MHC class II and CD86 by opposing E3 ubiquitin ligase-mediated turnover: the CD83 transmembrane domain blocks IL-10-driven MARCH1-mediated ubiquitination and degradation of these molecules in dendritic cells [PMID:21220452], and CD83 acts genetically upstream of MARCH8 in thymic epithelial cells, where deletion of March8 rescues the impaired CD4+ T cell selection of CD83 transmembrane mutants [PMID:27503069]. This stromal/thymic CD83 function is required for CD4+ single-positive thymocyte development, since the requirement maps to the thymic environment rather than the thymocytes themselves [PMID:11955430], and CD83 likewise sustains surface MHC class II on peripheral B cells and DCs by limiting its internalization [PMID:17804692]. Beyond antigen presentation, CD83 is cell-intrinsically required across multiple immune lineages — in B cells for germinal center composition and antibody responses [PMID:26983787], in regulatory T cells for differentiation and resolution of inflammation [PMID:29875316], and in DCs, macrophages, and microglia as a restraint on pro-inflammatory activation, with conditional deletion aggravating EAE, colitis, and autoimmunity while enhancing bacterial clearance [PMID:25204675, PMID:31527313, PMID:37528070, PMID:36875129]. Membrane CD83 also functions in the immunological synapse, enhancing intracellular calcium release in interacting T cells [PMID:24436459] and transducing an inhibitory homotypic signal through suppression of p38α phosphorylation [PMID:25204675]. The soluble form (generated by shedding and by alternative splicing) is immunosuppressive [PMID:11431426, PMID:15905506]: it binds the TLR4 co-receptor MD-2 on CD14+ monocytes, triggering IRAK-1 degradation and COX-2–dependent induction of IDO, IL-10, and PGE2 that suppress T cell proliferation [PMID:22065790, PMID:28193829], an IDO/TGF-β axis that resolves autoimmune arthritis and uveitis in vivo [PMID:30050530, PMID:31001257]. CD83 expression is controlled at the transcriptional level by an IRF/NF-κB ternary promoter complex driving maturation-specific induction [PMID:23339870] and post-transcriptionally by a coding-region RNA element that, via HuR and APRIL/ANP32B, directs CRM1-dependent nuclear export of CD83 mRNA [PMID:16484227, PMID:17178712]; the protein is further regulated by GRAIL-mediated ubiquitination at cytoplasmic lysines K168/K183 [PMID:19542455] and by GRASP55-dependent glycosylation and surface trafficking through its C-terminal TELV motif [PMID:25701785].","teleology":[{"year":2000,"claim":"Established that CD83 surface expression depends on a specialized nucleocytoplasmic step, revealing that CD83 mRNA export is rate-limiting for protein production.","evidence":"Pharmacological block of eIF-5A hypusination (GC7) and analysis of CD83 mRNA export plus DC-mediated T cell activation","pmids":["10790432"],"confidence":"Medium","gaps":["Indirect pharmacological mechanism","cis-element and trans-factors not yet identified","did not define the export receptor"]},{"year":2001,"claim":"First defined the soluble CD83 ectodomain as a functional inhibitor, showing CD83 binds a non-homophilic ligand on DCs and suppresses DC maturation and T cell proliferation.","evidence":"Recombinant hCD83ext binding and DC maturation / T cell proliferation assays in vitro","pmids":["11748282"],"confidence":"High","gaps":["Ligand identity not determined","in vitro only","molecular mechanism of inhibition unresolved"]},{"year":2001,"claim":"Characterized CD83 as an adhesion receptor with a sialylated counterreceptor, and showed soluble CD83 is generated by shedding rather than new synthesis.","evidence":"CD83-Ig fusion binding, neuraminidase treatment, immunoprecipitation of a 72-kDa counterreceptor, and shedding analysis by ELISA/Western with synthesis inhibition","pmids":["11238630","11431426"],"confidence":"Medium","gaps":["72-kDa counterreceptor not molecularly identified","shedding protease unknown"]},{"year":2002,"claim":"Demonstrated a non-redundant in vivo requirement for CD83 in thymic stroma for CD4+ T cell development, defining its developmental role.","evidence":"CD83-/- mice with reciprocal thymocyte/bone-marrow adoptive transfer and flow cytometry","pmids":["11955430"],"confidence":"High","gaps":["Molecular mechanism in TECs not defined at this stage","did not connect to MHC II regulation"]},{"year":2005,"claim":"Resolved how soluble CD83 arises and functions, identifying splice variants encoding soluble protein, disulfide dimerization at C129, and intracellular trafficking through Golgi/recycling endosomes.","evidence":"RT-PCR splice variant mapping with recombinant protein MLR assays; C129S mutagenesis; immunofluorescence colocalization with endocytosis and cathepsin inhibition","pmids":["15905506","15721284","15746244"],"confidence":"Medium","gaps":["Relative in vivo contribution of splicing vs shedding to sCD83 pool unclear","trafficking machinery only partly defined"]},{"year":2006,"claim":"Defined the post-transcriptional control of CD83, identifying a coding-region RNA element bound by HuR and the cofactor APRIL/ANP32B that routes the mRNA through CRM1-dependent export.","evidence":"RNA-binding assays, reporter constructs, RNAi, leptomycin B, dominant-negative Nup214, and APRIL phosphosite mutagenesis","pmids":["16484227","17178712"],"confidence":"High","gaps":["Structural basis of HuR-element recognition unresolved","how this pathway is coupled to DC maturation signals unclear"]},{"year":2007,"claim":"Established CD83 as an intrinsic enhancer of DC immunostimulatory capacity and a stabilizer of surface MHC class II on B cells and DCs.","evidence":"siRNA knockdown in monocyte-derived DCs with T cell proliferation/cytokine readouts; CD83-/- mice with MHC II surface vs intracellular and internalization assays","pmids":["17442926","17804692"],"confidence":"High","gaps":["Mechanism linking CD83 to reduced MHC II internalization not yet molecular","no ligase identified at this point"]},{"year":2009,"claim":"Identified the E3 ligase GRAIL as a regulator of CD83 protein stability, mapping ubiquitination to cytoplasmic K168/K183 and linking CD83 to T cell costimulation.","evidence":"GRAIL transduction and domain/lysine mutagenesis, ubiquitination and proteasome assays, RNAi rescue, and CD4+ T cell activation assays","pmids":["19542455"],"confidence":"High","gaps":["In vivo relevance of GRAIL-CD83 axis not tested","stoichiometry of degradation unclear"]},{"year":2011,"claim":"Defined the dominant membrane mechanism by which CD83 sustains antigen presentation: its transmembrane domain antagonizes MARCH1-mediated ubiquitination of MHC II and CD86, while the soluble form was shown to act via monocyte COX-2/PGE2.","evidence":"ENU TM-domain mutant mice with MARCH1 ubiquitination and IL-10 assays; T cell assays with COX-2 inhibitor NS-398 and monocyte depletion/transwell","pmids":["21220452","22065790"],"confidence":"High","gaps":["How the TM domain physically blocks MARCH1 unresolved","molecular target of sCD83 on monocytes not yet identified in 2011"]},{"year":2014,"claim":"Dissected CD83 transcriptional control and synapse signaling functions, defining an IRF/NF-κB promoter complex, a homotypic inhibitory signal via p38α, and enhancement of T cell calcium release.","evidence":"ChIP/EMSA/reporter/mutagenesis of the CD83 promoter; conditional DC-CD83 KO colitis model with truncation mutants and p38 assays; siRNA/antibody blocking with calcium imaging","pmids":["23339870","25204675","24436459"],"confidence":"Medium","gaps":["Receptor mediating homotypic signal unidentified","link between calcium enhancement and downstream T cell fate unclear"]},{"year":2016,"claim":"Extended CD83's MARCH-antagonist role to thymic MARCH8 via genetic epistasis, and established a B cell-intrinsic requirement for activation and germinal center responses.","evidence":"March8/Cd83 double-mutant mice with TEC MHC II and T cell selection analysis; B cell-specific conditional KO with mixed bone marrow chimeras, GC and IgE analysis, Borrelia infection","pmids":["27503069","26983787"],"confidence":"High","gaps":["Whether membrane CD83 directly contacts MARCH ligases is not shown","GC dark/light zone mechanism incompletely defined"]},{"year":2015,"claim":"Identified GRASP55 as a direct CD83 partner controlling glycosylation and surface trafficking via the C-terminal TELV motif.","evidence":"Yeast two-hybrid, co-IP, TELV-motif mutagenesis with glycosylation and surface expression readouts","pmids":["25701785"],"confidence":"Medium","gaps":["Single-lab interaction without reciprocal in vivo validation","how glycosylation state alters CD83 function unclear"]},{"year":2017,"claim":"Identified the receptor for soluble CD83, showing it binds MD-2 within the TLR4/MD-2 complex on monocytes to drive IRAK-1 degradation and COX-2-dependent IDO/IL-10/PGE2.","evidence":"Binding assays identifying MD-2, IRAK-1 degradation, downstream mediator induction with COX-2 inhibition, and T cell assays","pmids":["28193829"],"confidence":"Medium","gaps":["Direct structural sCD83-MD-2 interaction not solved","whether membrane CD83 uses the same receptor unknown"]},{"year":2018,"claim":"Established cell-intrinsic CD83 requirements in regulatory T cells and defined soluble CD83 tolerogenic mechanisms in autoimmunity through cytoskeletal/calcium synapse disruption.","evidence":"Treg-specific conditional KO with scRNA-seq and autoimmunity models; EAU model with sCD83 imaging of F-actin and calcium microdomains","pmids":["29875316","30050530"],"confidence":"Medium","gaps":["Molecular sensor linking CD83 to Treg gene program unknown","synapse-disruption mechanism single-lab"]},{"year":2019,"claim":"Defined DC-intrinsic CD83 as a brake on T cell priming and supporter of Treg function, and the sCD83 IDO/TGF-β axis as a resolution pathway in arthritis.","evidence":"DC-specific conditional KO with bacterial infection and EAE models; AIA model with IDO inhibitor and anti-TGF-β blockade plus osteoclast/Treg readouts","pmids":["31527313","31001257"],"confidence":"High","gaps":["How CD83 loss elevates DC IL-2/IL-12 mechanistically unresolved","in vivo source of IDO-inducing sCD83 receptor not pinpointed"]},{"year":2023,"claim":"Extended CD83's anti-inflammatory checkpoint role to tissue macrophages and microglia, showing it sustains alternatively activated/pro-resolving phenotypes.","evidence":"Macrophage- and microglia-specific conditional KO with STAT-6/receptor/cytokine and phagocytosis readouts, wound healing, scRNA-seq, and EAE","pmids":["36875129","37528070"],"confidence":"Medium","gaps":["Whether CD83 acts membrane-intrinsically or via shedding in these cells unclear","direct molecular effectors downstream of CD83 in myeloid cells undefined"]},{"year":null,"claim":"The molecular identity of the membrane CD83 receptor/ligand mediating its costimulatory, calcium, and homotypic signals, and the structural basis for its antagonism of MARCH ligases, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined membrane CD83 receptor despite multiple functional readouts","no structure of CD83-MARCH or CD83-MD-2 complexes","relative in vivo contribution of membrane vs soluble CD83 not partitioned"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[10,11,12]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[18,31]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,20]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[20,21]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[20]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,10,22,24]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[10,11,12]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[7,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[18,19,31]}],"complexes":["TLR4/MD-2 co-receptor complex (soluble CD83 binding partner)"],"partners":["MD-2","MARCH1","MARCH8","RNF128","ELAVL1","ANP32B","GORASP2","CD86"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01151","full_name":"CD83 antigen","aliases":["B-cell activation protein","Cell surface protein HB15"],"length_aa":205,"mass_kda":23.0,"function":"Transmembrane glycoprotein predominantly found on the surface of many immune cells including dendritic cells or lymphocytes that plays various roles in immune response regulation. Plays an essential role in CD4(+) T-selection, differentiation and stability by regulating the activity of the major E3 ubiquitin ligase responsible for controlling MHCII trafficking MARCHF8. Also inhibits MARCHF1 association with MHCII or CD86 to prevent their ubiquitination and subsequent degradation (PubMed:21220452). In addition, acts as an important modulator of protective responses against acute infections (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q01151/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD83","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD83","total_profiled":1310},"omim":[{"mim_id":"618806","title":"T-CELL LYMPHOPENIA, INFANTILE, WITH OR WITHOUT NAIL DYSTROPHY, AUTOSOMAL DOMINANT; TLIND","url":"https://www.omim.org/entry/618806"},{"mim_id":"614372","title":"MANNOSE-BINDING LECTIN DEFICIENCY; MBLD","url":"https://www.omim.org/entry/614372"},{"mim_id":"609888","title":"LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1","url":"https://www.omim.org/entry/609888"},{"mim_id":"604534","title":"CD83 ANTIGEN; CD83","url":"https://www.omim.org/entry/604534"},{"mim_id":"604472","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 13; TNFSF13","url":"https://www.omim.org/entry/604472"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":197.9}],"url":"https://www.proteinatlas.org/search/CD83"},"hgnc":{"alias_symbol":["HB15","BL11"],"prev_symbol":[]},"alphafold":{"accession":"Q01151","domains":[{"cath_id":"2.60.40.10","chopping":"17-128","consensus_level":"high","plddt":78.2339,"start":17,"end":128},{"cath_id":"1.20.5","chopping":"134-166","consensus_level":"medium","plddt":85.5897,"start":134,"end":166}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01151","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01151-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01151-F1-predicted_aligned_error_v6.png","plddt_mean":72.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD83","jax_strain_url":"https://www.jax.org/strain/search?query=CD83"},"sequence":{"accession":"Q01151","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01151.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01151/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01151"}},"corpus_meta":[{"pmid":"7706722","id":"PMC_7706722","title":"Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7706722","citation_count":641,"is_preprint":false},{"pmid":"20484028","id":"PMC_20484028","title":"Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20484028","citation_count":330,"is_preprint":false},{"pmid":"16203865","id":"PMC_16203865","title":"IL-18-induced CD83+CCR7+ NK helper cells.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16203865","citation_count":236,"is_preprint":false},{"pmid":"12072358","id":"PMC_12072358","title":"CD83 on dendritic cells: more than just a marker for maturation.","date":"2002","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12072358","citation_count":192,"is_preprint":false},{"pmid":"21220452","id":"PMC_21220452","title":"CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21220452","citation_count":188,"is_preprint":false},{"pmid":"11955430","id":"PMC_11955430","title":"CD83 expression influences CD4+ T cell development in the thymus.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11955430","citation_count":174,"is_preprint":false},{"pmid":"17301951","id":"PMC_17301951","title":"CD83 expression on dendritic cells and T cells: correlation with effective immune responses.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17301951","citation_count":168,"is_preprint":false},{"pmid":"11748282","id":"PMC_11748282","title":"The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11748282","citation_count":157,"is_preprint":false},{"pmid":"10880386","id":"PMC_10880386","title":"Human decidua contains potent immunostimulatory CD83(+) dendritic cells.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10880386","citation_count":145,"is_preprint":false},{"pmid":"31231400","id":"PMC_31231400","title":"CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31231400","citation_count":139,"is_preprint":false},{"pmid":"10790432","id":"PMC_10790432","title":"Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10790432","citation_count":122,"is_preprint":false},{"pmid":"17334966","id":"PMC_17334966","title":"CD83: an update on functions and prospects of the maturation marker of dendritic cells.","date":"2007","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/17334966","citation_count":120,"is_preprint":false},{"pmid":"18292234","id":"PMC_18292234","title":"Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18292234","citation_count":120,"is_preprint":false},{"pmid":"11090084","id":"PMC_11090084","title":"Expression of CCR6 and CD83 by cytokine-activated human neutrophils.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11090084","citation_count":115,"is_preprint":false},{"pmid":"12594843","id":"PMC_12594843","title":"Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12594843","citation_count":115,"is_preprint":false},{"pmid":"11431426","id":"PMC_11431426","title":"A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera.","date":"2001","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11431426","citation_count":114,"is_preprint":false},{"pmid":"32362900","id":"PMC_32362900","title":"The CD83 Molecule - An Important Immune Checkpoint.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32362900","citation_count":110,"is_preprint":false},{"pmid":"18329338","id":"PMC_18329338","title":"CD83 regulates lymphocyte maturation, activation and homeostasis.","date":"2008","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18329338","citation_count":99,"is_preprint":false},{"pmid":"17442926","id":"PMC_17442926","title":"CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17442926","citation_count":98,"is_preprint":false},{"pmid":"11884422","id":"PMC_11884422","title":"Cutting edge: CD83 regulates the development of cellular immunity.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11884422","citation_count":90,"is_preprint":false},{"pmid":"11238630","id":"PMC_11238630","title":"CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected].","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11238630","citation_count":83,"is_preprint":false},{"pmid":"26983787","id":"PMC_26983787","title":"CD83 Modulates B Cell Activation and Germinal Center Responses.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26983787","citation_count":80,"is_preprint":false},{"pmid":"17878352","id":"PMC_17878352","title":"CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17878352","citation_count":80,"is_preprint":false},{"pmid":"15114667","id":"PMC_15114667","title":"CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15114667","citation_count":72,"is_preprint":false},{"pmid":"10567699","id":"PMC_10567699","title":"Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10567699","citation_count":71,"is_preprint":false},{"pmid":"12403928","id":"PMC_12403928","title":"Role of CD83 in the immunomodulation of dendritic cells.","date":"2002","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12403928","citation_count":69,"is_preprint":false},{"pmid":"12452842","id":"PMC_12452842","title":"Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease.","date":"2002","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12452842","citation_count":69,"is_preprint":false},{"pmid":"16484227","id":"PMC_16484227","title":"Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16484227","citation_count":66,"is_preprint":false},{"pmid":"18424708","id":"PMC_18424708","title":"CD83 expression in CD4+ T cells modulates inflammation and autoimmunity.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18424708","citation_count":65,"is_preprint":false},{"pmid":"15383588","id":"PMC_15383588","title":"Homologs of CD83 from elasmobranch and teleost fish.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15383588","citation_count":64,"is_preprint":false},{"pmid":"27503069","id":"PMC_27503069","title":"Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27503069","citation_count":61,"is_preprint":false},{"pmid":"19171763","id":"PMC_19171763","title":"Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19171763","citation_count":61,"is_preprint":false},{"pmid":"11536161","id":"PMC_11536161","title":"Human monocyte-derived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11536161","citation_count":60,"is_preprint":false},{"pmid":"16913569","id":"PMC_16913569","title":"CD83: a regulatory molecule of the immune system with great potential for therapeutic application.","date":"2006","source":"Journal of medical and dental sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16913569","citation_count":57,"is_preprint":false},{"pmid":"28193829","id":"PMC_28193829","title":"Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28193829","citation_count":57,"is_preprint":false},{"pmid":"14687618","id":"PMC_14687618","title":"The soluble form of CD83 is present at elevated levels in a number of hematological malignancies.","date":"2004","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/14687618","citation_count":57,"is_preprint":false},{"pmid":"9799334","id":"PMC_9799334","title":"The mouse Cd83 gene: structure, domain organization, and chromosome localization.","date":"1998","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9799334","citation_count":53,"is_preprint":false},{"pmid":"17178712","id":"PMC_17178712","title":"Analysis of nucleocytoplasmic trafficking of the HuR ligand APRIL and its influence on CD83 expression.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17178712","citation_count":53,"is_preprint":false},{"pmid":"10967030","id":"PMC_10967030","title":"Activation-induced expression of murine CD83 on T cells and identification of a specific CD83 ligand on murine B cells.","date":"2000","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10967030","citation_count":52,"is_preprint":false},{"pmid":"15905506","id":"PMC_15905506","title":"Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905506","citation_count":52,"is_preprint":false},{"pmid":"11588047","id":"PMC_11588047","title":"Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11588047","citation_count":52,"is_preprint":false},{"pmid":"29875316","id":"PMC_29875316","title":"CD83 expression is essential for Treg cell differentiation and stability.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29875316","citation_count":51,"is_preprint":false},{"pmid":"17266176","id":"PMC_17266176","title":"CD83 is a regulator of murine B cell function in vivo.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17266176","citation_count":49,"is_preprint":false},{"pmid":"18001846","id":"PMC_18001846","title":"Dendritic cell CD83: a therapeutic target or innocent bystander?","date":"2007","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18001846","citation_count":47,"is_preprint":false},{"pmid":"17804692","id":"PMC_17804692","title":"CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells.","date":"2007","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17804692","citation_count":45,"is_preprint":false},{"pmid":"17291220","id":"PMC_17291220","title":"A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts.","date":"2007","source":"Transplant international : official journal of the European Society for Organ Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/17291220","citation_count":45,"is_preprint":false},{"pmid":"32437331","id":"PMC_32437331","title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32437331","citation_count":44,"is_preprint":false},{"pmid":"24424524","id":"PMC_24424524","title":"Soluble CD83 ameliorates experimental colitis in mice.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24424524","citation_count":43,"is_preprint":false},{"pmid":"17710154","id":"PMC_17710154","title":"CD83 modulates B cell function in vitro: increased IL-10 and reduced Ig secretion by CD83Tg B cells.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17710154","citation_count":43,"is_preprint":false},{"pmid":"19844997","id":"PMC_19844997","title":"Neuronal expression of Cd36, Cd44, and Cd83 antigen transcripts maps to distinct and specific murine brain circuits.","date":"2009","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19844997","citation_count":43,"is_preprint":false},{"pmid":"18817880","id":"PMC_18817880","title":"A highly phagocytic cell line TO from Atlantic salmon is CD83 positive and M-CSFR negative, indicating a dendritic-like cell type.","date":"2008","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18817880","citation_count":41,"is_preprint":false},{"pmid":"9271021","id":"PMC_9271021","title":"Hodgkin's cells express CD83, a dendritic cell lineage associated antigen.","date":"1997","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9271021","citation_count":41,"is_preprint":false},{"pmid":"15322158","id":"PMC_15322158","title":"A novel mutation in CD83 results in the development of a unique population of CD4+ T cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15322158","citation_count":40,"is_preprint":false},{"pmid":"37528070","id":"PMC_37528070","title":"Microglial expression of CD83 governs cellular activation and restrains neuroinflammation in experimental autoimmune encephalomyelitis.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37528070","citation_count":40,"is_preprint":false},{"pmid":"11642602","id":"PMC_11642602","title":"Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines.","date":"2001","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11642602","citation_count":40,"is_preprint":false},{"pmid":"19465512","id":"PMC_19465512","title":"Decreased small airway and alveolar CD83+ dendritic cells in COPD.","date":"2009","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/19465512","citation_count":40,"is_preprint":false},{"pmid":"25204675","id":"PMC_25204675","title":"Dendritic cell CD83 homotypic interactions regulate inflammation and promote mucosal homeostasis.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25204675","citation_count":39,"is_preprint":false},{"pmid":"22065790","id":"PMC_22065790","title":"CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22065790","citation_count":39,"is_preprint":false},{"pmid":"12857898","id":"PMC_12857898","title":"Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12857898","citation_count":38,"is_preprint":false},{"pmid":"28659471","id":"PMC_28659471","title":"The Nucleocapsid Protein and Nonstructural Protein 10 of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus Enhance CD83 Production via NF-κB and Sp1 Signaling Pathways.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28659471","citation_count":37,"is_preprint":false},{"pmid":"19542455","id":"PMC_19542455","title":"The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19542455","citation_count":37,"is_preprint":false},{"pmid":"25563385","id":"PMC_25563385","title":"An immunohistochemical study of CD83- and CD1a-positive dendritic cells in the decidua of women with recurrent spontaneous abortion.","date":"2015","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/25563385","citation_count":37,"is_preprint":false},{"pmid":"31527313","id":"PMC_31527313","title":"CD83 orchestrates immunity toward self and non-self in dendritic cells.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31527313","citation_count":36,"is_preprint":false},{"pmid":"17911597","id":"PMC_17911597","title":"Unique features and distribution of the chicken CD83+ cell.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17911597","citation_count":36,"is_preprint":false},{"pmid":"34531862","id":"PMC_34531862","title":"Eubacterium rectale Attenuates HSV-1 Induced Systemic Inflammation in Mice by Inhibiting CD83.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34531862","citation_count":36,"is_preprint":false},{"pmid":"11412308","id":"PMC_11412308","title":"Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin.","date":"2001","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11412308","citation_count":34,"is_preprint":false},{"pmid":"12113551","id":"PMC_12113551","title":"Upregulation of co-stimulatory molecule expression and dendritic cell marker (CD83) on B cells in periodontal disease.","date":"2002","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/12113551","citation_count":34,"is_preprint":false},{"pmid":"12950676","id":"PMC_12950676","title":"Enhanced activation of CD83-positive T cells.","date":"2003","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12950676","citation_count":32,"is_preprint":false},{"pmid":"15721284","id":"PMC_15721284","title":"CD83 is a dimer: Comparative analysis of monomeric and dimeric isoforms.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15721284","citation_count":32,"is_preprint":false},{"pmid":"25151500","id":"PMC_25151500","title":"Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo.","date":"2014","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25151500","citation_count":32,"is_preprint":false},{"pmid":"15746244","id":"PMC_15746244","title":"CD83 localization in a recycling compartment of immature human monocyte-derived dendritic cells.","date":"2005","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15746244","citation_count":32,"is_preprint":false},{"pmid":"27837105","id":"PMC_27837105","title":"The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27837105","citation_count":31,"is_preprint":false},{"pmid":"18701714","id":"PMC_18701714","title":"The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18701714","citation_count":31,"is_preprint":false},{"pmid":"11922761","id":"PMC_11922761","title":"Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.","date":"2002","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/11922761","citation_count":31,"is_preprint":false},{"pmid":"12687354","id":"PMC_12687354","title":"Expression of CD83 in the murine immune system.","date":"2003","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12687354","citation_count":31,"is_preprint":false},{"pmid":"18056445","id":"PMC_18056445","title":"CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18056445","citation_count":30,"is_preprint":false},{"pmid":"36875129","id":"PMC_36875129","title":"CD83 expressed by macrophages is an important immune checkpoint molecule for the resolution of inflammation.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36875129","citation_count":29,"is_preprint":false},{"pmid":"17023048","id":"PMC_17023048","title":"Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17023048","citation_count":29,"is_preprint":false},{"pmid":"31001257","id":"PMC_31001257","title":"Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31001257","citation_count":29,"is_preprint":false},{"pmid":"25800093","id":"PMC_25800093","title":"CD83 is required for the induction of protective immunity by a DNA vaccine in a teleost model.","date":"2015","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25800093","citation_count":28,"is_preprint":false},{"pmid":"31035565","id":"PMC_31035565","title":"Rainbow Trout Red Blood Cells Exposed to Viral Hemorrhagic Septicemia Virus Up-Regulate Antigen-Processing Mechanisms and MHC I&II, CD86, and CD83 Antigen-presenting Cell Markers.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31035565","citation_count":28,"is_preprint":false},{"pmid":"26286117","id":"PMC_26286117","title":"Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26286117","citation_count":27,"is_preprint":false},{"pmid":"21277328","id":"PMC_21277328","title":"Activated T cells induce rapid CD83 expression on B cells by engagement of CD40.","date":"2011","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/21277328","citation_count":27,"is_preprint":false},{"pmid":"9566553","id":"PMC_9566553","title":"Low CD83, but normal MHC class II and costimulatory molecule expression, on spleen dendritic cells from HIV+ patients.","date":"1998","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/9566553","citation_count":27,"is_preprint":false},{"pmid":"29351987","id":"PMC_29351987","title":"CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.","date":"2018","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/29351987","citation_count":26,"is_preprint":false},{"pmid":"24436459","id":"PMC_24436459","title":"Dendritic cell membrane CD83 enhances immune responses by boosting intracellular calcium release in T lymphocytes.","date":"2014","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/24436459","citation_count":26,"is_preprint":false},{"pmid":"36769151","id":"PMC_36769151","title":"CD83 Regulates the Immune Responses in Inflammatory Disorders.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36769151","citation_count":24,"is_preprint":false},{"pmid":"19234177","id":"PMC_19234177","title":"Engagement of CD83 on B cells modulates B cell function in vivo.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19234177","citation_count":24,"is_preprint":false},{"pmid":"30050530","id":"PMC_30050530","title":"Soluble CD83 Alleviates Experimental Autoimmune Uveitis by Inhibiting Filamentous Actin-Dependent Calcium Release in Dendritic Cells.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30050530","citation_count":24,"is_preprint":false},{"pmid":"26661374","id":"PMC_26661374","title":"CD1a+ and CD83+ Langerhans cells are reduced in lower lip squamous cell carcinoma.","date":"2015","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26661374","citation_count":23,"is_preprint":false},{"pmid":"20561589","id":"PMC_20561589","title":"Expression of Scophthalmus maximus CD83 correlates with bacterial infection and antigen stimulation.","date":"2010","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20561589","citation_count":23,"is_preprint":false},{"pmid":"11937733","id":"PMC_11937733","title":"In situ localization of CD83-positive dendritic cells in psoriatic lesions.","date":"2002","source":"Dermatology (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/11937733","citation_count":22,"is_preprint":false},{"pmid":"18544574","id":"PMC_18544574","title":"CD83 regulates splenic B cell maturation and peripheral B cell homeostasis.","date":"2008","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18544574","citation_count":20,"is_preprint":false},{"pmid":"35054916","id":"PMC_35054916","title":"Tilting the Balance: Therapeutic Prospects of CD83 as a Checkpoint Molecule Controlling Resolution of Inflammation.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35054916","citation_count":20,"is_preprint":false},{"pmid":"23461413","id":"PMC_23461413","title":"Differentiation and activation of equine monocyte-derived dendritic cells are not correlated with CD206 or CD83 expression.","date":"2013","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23461413","citation_count":20,"is_preprint":false},{"pmid":"17526743","id":"PMC_17526743","title":"Soluble CD14 and CD83 from human neonatal antigen-presenting cells are inducible by commensal bacteria and suppress allergen-induced human neonatal Th2 differentiation.","date":"2007","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17526743","citation_count":20,"is_preprint":false},{"pmid":"23339870","id":"PMC_23339870","title":"Multiple interferon regulatory factor and NF-κB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23339870","citation_count":20,"is_preprint":false},{"pmid":"25701785","id":"PMC_25701785","title":"CD83 and GRASP55 interact in human dendritic cells.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25701785","citation_count":19,"is_preprint":false},{"pmid":"28267648","id":"PMC_28267648","title":"Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy.","date":"2017","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/28267648","citation_count":19,"is_preprint":false},{"pmid":"26561569","id":"PMC_26561569","title":"Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26561569","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47436,"output_tokens":9096,"usd":0.139374,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19292,"output_tokens":5612,"usd":0.11838,"stage2_stop_reason":"end_turn"},"total_usd":0.257754,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"The extracellular Ig domain of CD83 (hCD83ext) binds a ligand expressed on both immature and mature dendritic cells; this binding is not homophilic (immature DCs do not express CD83 yet bind hCD83ext), and soluble hCD83ext inhibits DC maturation by downmodulating CD80 and CD83 expression, and inhibits DC-dependent allogeneic and peptide-specific T cell proliferation in a concentration-dependent manner in vitro.\",\n      \"method\": \"Recombinant protein expression of soluble extracellular domain; binding assays on immature and mature DCs; DC maturation assays; allogeneic and peptide-specific T cell proliferation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — recombinant protein reconstitution, binding assays, functional inhibition assays with multiple readouts, single lab\",\n      \"pmids\": [\"11748282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD83 expression by thymic epithelial and dendritic cells is required for CD4+ single-positive thymocyte development: CD83-/- mice show a specific block in CD4+ SP thymocyte generation resulting in 75-90% reduction in peripheral CD4+ T cells, predominantly naive. Wild-type thymocytes transferred into CD83-/- mice fail to develop into mature CD4+ T cells, while CD83-/- thymocytes develop normally in wild-type hosts, demonstrating the requirement is in the stromal/thymic environment.\",\n      \"method\": \"CD83-/- mouse model; adoptive transfer of thymocytes and bone marrow stem cells into CD83-/- vs. wild-type hosts; flow cytometric analysis of T cell subsets\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with defined cellular phenotype, reciprocal adoptive transfer epistasis, independently replicated by multiple subsequent studies\",\n      \"pmids\": [\"11955430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD83 mRNA is transported from the nucleus to the cytoplasm via a specific CRM1-dependent nuclear export pathway. Inhibition of the hypusine modification of eIF-5A (by GC7) prevents CD83 surface expression by blocking nucleocytoplasmic translocation of CD83 mRNA, and this also significantly inhibits DC-mediated T lymphocyte activation.\",\n      \"method\": \"Pharmacological inhibition of hypusine formation (GC7); analysis of CD83 mRNA nuclear export; DC-mediated T cell activation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with defined target, mRNA transport readout, functional T cell assay; single lab, indirect mechanism\",\n      \"pmids\": [\"10790432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD83 is an adhesion receptor: a soluble CD83-Ig fusion protein binds peripheral blood monocytes and a subset of activated CD3+CD8+ T lymphocytes. Binding to the CD8+ T cell line HPB-ALL is neuraminidase-sensitive, implicating sialic acid modification of a 72-kDa counterreceptor. Full-length CD83 expressed by a transfected carcinoma line mediates CD83-dependent adhesion to HPB-ALL cells.\",\n      \"method\": \"CD83-Ig fusion protein binding assays; neuraminidase treatment; immunoprecipitation of 72-kDa counterreceptor; adhesion assays with CD83-transfected cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays, immunoprecipitation, neuraminidase-sensitive adhesion, single lab\",\n      \"pmids\": [\"11238630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Soluble CD83 (sCD83) is released from membrane CD83-positive cells by shedding (not de novo synthesis during short-term culture) and is detectable in normal human sera. Both activated B cell lines and monocyte-derived DCs release sCD83 proportionally to their mCD83 expression level.\",\n      \"method\": \"sCD83-specific ELISA; Western blotting; inhibition of de novo protein synthesis; culture of B cell lines and monocyte-derived DCs\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ELISA and Western blot with protein synthesis inhibition to distinguish shedding from new synthesis; single lab, two complementary methods\",\n      \"pmids\": [\"11431426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD83 mRNA contains four alternative splice variants in unstimulated PBMCs; the smallest splice product can be efficiently translated into a soluble CD83 protein. Recombinant soluble CD83 from this variant strongly inhibits T cell proliferation in MLR. Stimulation with PHA, TNF-alpha, or LPS upregulates full-length CD83 transcript and downregulates two of the three smaller splice variants.\",\n      \"method\": \"RT-PCR identification of splice variants; recombinant protein expression; MLR T cell proliferation assay; stimulation with mitogens/cytokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — recombinant protein with functional assay, splice variant characterization; single lab\",\n      \"pmids\": [\"15905506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD83 forms dimers via an intermolecular disulfide bond at cysteine 129. Mutation of C129 to serine abolishes dimerization. The monomeric mutant inhibits CD83 surface upregulation during DC maturation and inhibits DC-mediated allogeneic T cell stimulation in vitro, indicating functional activity of the soluble form is retained as a monomer.\",\n      \"method\": \"Recombinant mutational analysis (C129S); biochemical analysis of dimerization; DC maturation assays; MLR allogeneic T cell stimulation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with mutagenesis, single lab, single study\",\n      \"pmids\": [\"15721284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD83 mRNA expression is post-transcriptionally regulated via a novel cis-acting structured RNA element in its coding region that binds HuR. HuR binding does not affect mRNA stability but is required for cytoplasmic accumulation of CD83 transcripts via the CRM1 nuclear export pathway. RNAi knockdown of HuR reduces CD83 expression; inhibition of CRM1 (leptomycin B) or overexpression of defective Nup214/CAN similarly diminishes cytoplasmic CD83 mRNA.\",\n      \"method\": \"RNA-binding assays; transient transfection with post-transcriptional regulatory element reporters; RNA interference; leptomycin B treatment; dominant-negative Nup214 overexpression; mRNA stability assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (RNAi, pharmacological inhibition, dominant-negative, RNA-binding assays, reporter assays) in single lab establishing HuR-CRM1 axis\",\n      \"pmids\": [\"16484227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"APRIL (ANP32B), a protein ligand of HuR, contributes to nuclear export and subsequent translation of CD83 mRNA. RNAi knockdown of APRIL reduces CD83 expression. Phosphorylation of APRIL at threonine 244 regulates its nuclear export and thereby modulates the nucleocytoplasmic translocation of CD83 mRNA. In contrast, pp32 (ANP32A) is dispensable for CD83 expression.\",\n      \"method\": \"RNA interference (RNAi); identification of NLS and NES of APRIL; phosphorylation mapping (T244); CD83 expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi with specific controls, mutagenesis of phosphorylation site, single lab\",\n      \"pmids\": [\"17178712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD83 knockdown by siRNA in monocyte-derived dendritic cells significantly diminishes DC-mediated T cell proliferation and alters cytokine expression during T cell priming, establishing CD83 as an enhancer of DC-mediated T cell stimulation. This was demonstrated without the use of viral infection or pharmacological inhibitors.\",\n      \"method\": \"siRNA knockdown of CD83 in immature monocyte-derived DCs; electroporation for delivery; allogeneic T cell proliferation assay; cytokine expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean siRNA knockdown with specific functional readouts (proliferation + cytokine), single lab\",\n      \"pmids\": [\"17442926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The transmembrane domain of CD83 blocks IL-10-driven, MARCH1-mediated ubiquitination and degradation of MHC class II and CD86 in dendritic cells. Mice with an ENU-induced mutation eliminating the CD83 transmembrane region show reduced surface MHC class II and CD86, demonstrating that the CD83 TM domain enhances MHC class II and CD86 expression by opposing MARCH1-dependent turnover.\",\n      \"method\": \"ENU mutagenesis screen generating TM-domain CD83 mutant mice; analysis of MHC class II and CD86 surface expression; MARCH1-dependent ubiquitination assays; IL-10 treatment\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with defined molecular mechanism (MARCH1 ubiquitination pathway), multiple orthogonal readouts, confirmed in follow-up study (PMID 27503069)\",\n      \"pmids\": [\"21220452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MARCH8 is the E3 ubiquitin ligase responsible for regulating surface MHC II in thymic epithelial cells (TECs). CD83 controls the ubiquitination of MHC II by MARCH8 in TECs: mice with the Cd83 anu/anu mutation (lacking functional CD83 TM domain) have impaired CD4+ T cell selection, and deletion of March8 in Cd83 anu/anu mice restores CD4+ T cell selection to normal levels, placing CD83 upstream of MARCH8-mediated MHC II regulation in TECs.\",\n      \"method\": \"March8-/- mice; Cd83 anu/anu mice; March8/Cd83 double-mutant mice; flow cytometric analysis of MHC II on cortical and medullary TECs; CD4+ T cell development and repertoire analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double KO rescue, clean cellular phenotype, orthogonal to PMID 21220452\",\n      \"pmids\": [\"27503069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRAIL, a transmembrane RING finger E3 ubiquitin ligase, ubiquitinates CD83 on lysine residues K168 and K183 (but not K192) in its cytoplasmic domain, leading to proteasomal degradation of CD83 on CD4+ T cells. GRAIL-mediated CD83 downregulation requires an intact extracellular protease-associated domain and an enzymatically active RING domain. GRAIL knockdown by RNAi elevates CD83 levels, and CD83 expression on CD4+ T cells contributes to T cell activation as a costimulatory molecule.\",\n      \"method\": \"Retroviral transduction of GRAIL; GRAIL domain mutants; ubiquitination assays identifying K168/K183; proteasome pathway analysis; RNAi knockdown of GRAIL; CD4+ T cell activation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro ubiquitination with specific lysine mutagenesis, domain mutagenesis, RNAi rescue, functional T cell activation readout; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19542455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EBV latent membrane protein 1 (LMP1) induces CD83 expression in B cells via NF-κB signaling. LMP1-mediated activation of the CD83 promoter is dependent on NF-κB, as shown by luciferase reporter assays using the CD83 promoter and LMP1 signaling mutants. Fusion constructs of the LMP1 TM domain with intracellular signaling domains of CD40, TNF-R1, or TNF-R2 similarly transactivate the CD83 promoter via NF-κB.\",\n      \"method\": \"Luciferase reporter assays with CD83 promoter; LMP1 signaling mutants; inducible LMP1 expression system; NF-κB pathway analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with multiple LMP1 mutants and chimeric constructs, NF-κB pathway confirmed; single lab\",\n      \"pmids\": [\"12857898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The human CD83 promoter activity in DCs is regulated by a ternary transcriptional complex consisting of an upstream regulatory element, a minimal promoter, and an enhancer containing IRF- and NF-κB binding sites. IRF-1, IRF-2, IRF-5, p50, p65, and cRel regulate maturation-specific CD83 expression; mutation of any IRF-binding site causes significant loss of promoter activity, while NF-κB overexpression enhances transcription.\",\n      \"method\": \"ChIP-on-chip microarray; biocomputational analysis; luciferase reporter assays; EMSA; ChIP with specific TF antibodies; site-directed mutagenesis of IRF-binding sites; NF-κB overexpression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (ChIP, EMSA, reporter, mutagenesis) in single study with rigorous controls\",\n      \"pmids\": [\"23339870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD83 expression by thymic stromal cells influences MHC class II surface expression on B cells, DCs, thymic epithelial cells, and peritoneal macrophages: CD83-/- mice show 25-50% reduction in surface MHC class II on splenic B cells and DCs due to increased internalization of class II from the surface of CD83-/- B cells. MHC class II transcription, intracellular expression, heterodimer structure, antigen processing, and antigen presentation are normal.\",\n      \"method\": \"CD83-/- mice; flow cytometry for MHC class II surface and intracellular expression; MHC class II internalization assays; MHC class II transcription analysis; antigen processing/presentation assays\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with multiple readouts distinguishing surface vs. intracellular MHC II, internalization assay mechanistically informative; single lab\",\n      \"pmids\": [\"17804692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD83 expression on CD4+ T cells confers immunosuppressive function: retroviral transduction of CD83 into naive CD4+CD25- T cells induces a regulatory phenotype accompanied by Foxp3 induction. CD83+Foxp3+ T cells suppress the effector phase of contact hypersensitivity in vivo and prevent paralysis in experimental autoimmune encephalomyelitis (EAE), associated with suppression of IFN-gamma and IL-17 and increase in IL-10.\",\n      \"method\": \"Retroviral transduction of CD83 into naive CD4+ T cells; in vitro functional assays; adoptive transfer into contact hypersensitivity and EAE mouse models; cytokine analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — retroviral gain-of-function with in vivo functional readouts, multiple disease models; single lab\",\n      \"pmids\": [\"18424708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD83 inhibits T cell proliferation and cytokine (IL-2, IFN-γ) production via monocytes: CD83 stimulates monocytes to produce prostaglandin E2 (PGE2) via NF-κB-dependent upregulation of COX-2. COX-2-selective inhibitor NS-398 fully prevents CD83-triggered inhibition of T cell responses, and neither IL-10 nor TGF-β mediates this effect.\",\n      \"method\": \"T cell proliferation assays; cytokine measurement (IL-2, IFN-γ, PGE2); COX-2 inhibitor (NS-398); NF-κB activation analysis; depletion of monocytes; transwell assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple readouts, monocyte requirement demonstrated; single lab\",\n      \"pmids\": [\"22065790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Soluble CD83 (sCD83) binds to myeloid differentiation factor-2 (MD-2), the co-receptor within the TLR4/MD-2 complex, on CD14+ monocytes. This binding rapidly degrades IRAK-1 and induces anti-inflammatory mediators IDO, IL-10, and PGE2 in a COX-2-dependent manner, leading to inhibition of T cell proliferation and IL-2 secretion and T cell unresponsiveness to further differentiation signals.\",\n      \"method\": \"Binding assays identifying MD-2 as sCD83 partner; IRAK-1 degradation assays; IDO/IL-10/PGE2 induction assays; COX-2 inhibition; T cell proliferation and cytokine assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding partner identification with functional pathway dissection, multiple downstream readouts; single lab\",\n      \"pmids\": [\"28193829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD83 engages in homotypic cell-cell contact interactions that inhibit pro-inflammatory DC responses. CD83 knockdown or cytoplasmic truncation abrogates the effects of homotypic binding. The inhibitory signal transduced by CD83 homotypic interaction operates via the MAPK pathway by inhibiting p38α phosphorylation. Conditional DC-specific CD83 KO mice develop exacerbated colitis, while mucosal CD83 overexpression protects against colitis.\",\n      \"method\": \"Conditional DC-specific CD83 KO mice; CD83 cytoplasmic truncation mutants; siRNA knockdown; colitis model (DSS); p38α phosphorylation assays; cell-cell contact assays; transwell controls\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO in vivo plus mechanistic pathway (p38 MAPK) with domain mutants; single lab\",\n      \"pmids\": [\"25204675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD83 protein localizes to the Golgi compartment and recycling endosomes in both immature and mature DCs. In immature DCs, CD83 cycles between endosomes and the cell surface; inhibition of endocytosis induces CD83 surface expression in immature DCs. During DC maturation, CD83 co-localizes with MHC class II in endocytic vesicles (exclusive to mature DCs), and the increase in surface CD83 results primarily from increased protein synthesis with contribution from regulated intracellular transport. Cathepsin inhibitors impair CD83 surface upregulation.\",\n      \"method\": \"Immunofluorescence co-localization with organelle markers; endocytosis inhibition; pulse-chase/protein synthesis analysis; cathepsin inhibitors; fractionation; live-cell imaging\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple localization methods with functional interventions (endocytosis inhibition, cathepsin inhibitors); single lab\",\n      \"pmids\": [\"15746244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GRASP55 interacts with CD83 in human dendritic cells, binding via the C-terminal TELV-motif of CD83. Mutation of the TELV-motif disrupts GRASP55 binding, alters CD83 glycosylation pattern, and reduces CD83 membrane surface expression. GRASP55 interaction with CD83 is induced during DC maturation and plays a role in CD83 glycosylation and surface trafficking.\",\n      \"method\": \"Yeast two-hybrid screening; co-immunoprecipitation; TELV-motif mutagenesis; glycosylation analysis; co-localization studies; DC maturation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid + co-IP interaction identification, mutagenesis of binding motif with functional readout (glycosylation, surface expression); single lab\",\n      \"pmids\": [\"25701785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"B cell-intrinsic CD83 is required for normal MHC class II and CD86 upregulation and B cell proliferation after stimulation. In vivo, B cell-specific CD83 conditional KO causes a shift in germinal center dark zone/light zone composition, an enhanced IgE response, and a competitive disadvantage in GC responses in mixed bone marrow chimeras. CD83 B-cKO mice show impaired bacterial clearance of Borrelia burgdorferi with a shift toward Th2 responses.\",\n      \"method\": \"B cell-specific CD83 conditional KO mice (CD83 B-cKO); mixed bone marrow chimeras; immunization experiments; germinal center analysis; IgG/IgE measurements; Borrelia burgdorferi infection model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with multiple orthogonal in vivo readouts and cell-intrinsic mechanism confirmed by bone marrow chimeras\",\n      \"pmids\": [\"26983787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Treg-intrinsic CD83 expression is essential for Treg differentiation upon activation. Treg-specific conditional CD83 KO mice show a pro-inflammatory phenotype, downregulation of Treg-specific differentiation markers, induction of an inflammatory profile, aggravated autoimmunity, and impaired resolution of inflammation.\",\n      \"method\": \"Treg-specific conditional CD83 KO mice; single-cell RNA-sequencing; flow cytometry for Treg markers; autoimmunity models; inflammatory resolution assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional cell-type-specific KO with defined phenotypic readouts, scRNA-seq; single lab\",\n      \"pmids\": [\"29875316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DC-specific deletion of CD83 (CD83ΔDC) results in elevated IL-2 production, increased CD25 and OX40L expression on DCs, enhanced antigen-specific T cell responses, compromised Treg suppressive functions, and reduced peripheral Treg numbers. In bacterial infection models, CD83ΔDC mice clear Salmonella typhimurium and Listeria monocytogenes more efficiently with increased DC IL-12. In EAE, autoimmune inflammation is dramatically aggravated with increased CNS cell influx and Th17 numbers.\",\n      \"method\": \"DC-specific conditional CD83 KO (CD83ΔDC) mice; bacterial infection (Salmonella, Listeria); EAE model; cytokine profiling; T cell subset analysis; Treg functional assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional DC-specific KO with multiple orthogonal in vivo models and defined cellular mechanisms; single lab with comprehensive readouts\",\n      \"pmids\": [\"31527313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CD83 in murine microglia restrains neuroinflammation: conditional deletion of CD83 in microglia results in an over-activated microglial state during EAE neuroinflammation, increased recruitment of pathogenic immune cells to the CNS, deterioration of resolving mechanisms, and exacerbated disease. CD83 expression is associated with pro-resolving microglial functions.\",\n      \"method\": \"Conditional CD83 KO in microglia; single-cell RNA-sequencing; EAE model; immune cell infiltration analysis; cytokine profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with scRNA-seq and in vivo disease model; single lab\",\n      \"pmids\": [\"37528070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CD83 functions as an immune checkpoint in macrophages: IL-4-stimulated alternatively activated macrophages express CD83, and conditional CD83 deletion in macrophages reduces inhibitory receptors (CD200R, MSR-1), decreases phagocytic capacity, reduces pSTAT-6 levels and Gata3 expression, increases pro-inflammatory mediators (TNF-α, IL-6, CXCL1, G-CSF), and enhances allo-reactive T cell stimulation with reduced Treg induction. In a wound healing model, CD83-deficient macrophages show increased inflammatory transcripts and altered tissue reconstitution.\",\n      \"method\": \"Conditional CD83 KO in macrophages (cKO); IL-4 stimulation; STAT-6 phosphorylation assays; cytokine measurement; phagocytosis assays; T cell proliferation assays; full-thickness excision wound healing model; gene expression analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional cell-type-specific KO with multiple mechanistic readouts (STAT-6, receptor expression, functional assays); single lab\",\n      \"pmids\": [\"36875129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Soluble CD83 alleviates experimental autoimmune uveitis (EAU) by inducing tolerogenic DCs through disruption of cytoskeletal (filamentous actin) rearrangements at the DC-T cell contact zone, leading to altered calcium microdomain localization and suppressed co-stimulatory molecule synaptic expression and calcium responses in DCs.\",\n      \"method\": \"EAU mouse model; flow cytometry; imaging studies of cytoskeletal rearrangements; calcium response assays in DCs; systemic and topical sCD83 application; co-stimulatory molecule expression analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo disease model with mechanistic imaging and calcium signaling readouts; single lab\",\n      \"pmids\": [\"30050530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Soluble CD83 enhances resolution of autoimmune antigen-induced arthritis via IDO induction: inhibition of IDO by 1-methyltryptophan completely abrogates sCD83 effects. TGF-β also mediates sCD83-induced reduction of bone destruction and cartilage damage. sCD83 reduces IL-17A, IFNγ, IL-6, TNFα, and RANKL expression, inhibits osteoclast differentiation, and increases regulatory T cell numbers in an IDO-TGF-β-dependent manner.\",\n      \"method\": \"Antigen-induced arthritis (AIA) mouse model; IDO inhibition (1-methyltryptophan); anti-TGF-β antibody blocking; cytokine quantification; osteoclast differentiation assays; Treg analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with pharmacological pathway dissection (IDO inhibitor, TGF-β blockade), multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"31001257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD38 engagement by agonistic anti-CD38 mAb on mature monocyte-derived DCs induces upregulation of CD83 expression and IL-12 secretion. Disruption of the CD38/CD31 interaction inhibits CD83 expression, IL-12 secretion, and MDDC-induced allogeneic T cell proliferation. CD38 is enzymatically active (cyclic ADP ribose synthesis) in mature DCs and its expression is NF-κB dependent.\",\n      \"method\": \"Anti-CD38 agonistic mAb stimulation; CD38/CD31 blocking; CD83 expression analysis; IL-12 secretion assays; T cell proliferation assays; NF-κB inhibition\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological/antibody manipulation with specific functional readouts; single lab\",\n      \"pmids\": [\"15114667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Activated T cells induce rapid CD83 expression on B cells via CD40 engagement: in vivo T cell activation induces CD83 on ~80% of B cells in draining lymph nodes without requiring TCR/MHC binding (antigen-non-specific bystander effect). This induction requires cell contact and is blocked by anti-CD40L antibody, demonstrating CD40-dependent, contact-mediated CD83 induction on B cells.\",\n      \"method\": \"T cell receptor transgenic mice; cognate peptide injection; CD40L-blocking antibody; transwell separation assays; MHC-mismatched co-culture controls; flow cytometry\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro genetic/antibody-blocking with multiple controls establishing CD40-dependence; single lab\",\n      \"pmids\": [\"21277328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Membrane CD83 on mature DCs enhances intracellular calcium release in T lymphocytes during DC-T cell interaction. siRNA knockdown of CD83 or antibody blocking of surface CD83 on mature DCs reduces both calcium signal amplitude and the proportion of responding T cells, and abrogates T cell signaling in the absence of extracellular calcium, indicating CD83 promotes calcium release from intracellular stores.\",\n      \"method\": \"siRNA knockdown; anti-CD83 mAb blocking; calcium indicator (Fluo-4-AM); flow cytometry; confocal microscopy; CFSE proliferation assay; calcium-free medium experiments\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and antibody blocking with calcium imaging by multiple methods; single lab\",\n      \"pmids\": [\"24436459\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD83 is a type I transmembrane immunoglobulin superfamily glycoprotein whose membrane-bound form on mature dendritic cells, thymic epithelial cells, activated B and T cells, macrophages, and microglia promotes MHC class II and CD86 surface expression by opposing MARCH1/MARCH8-mediated ubiquitination and degradation, regulates CD4+ T cell development in the thymus, modulates DC activation state via homotypic interactions through p38 MAPK inhibition, enhances T cell calcium signaling and co-stimulation, and controls B cell maturation and germinal center responses; its soluble form (generated by alternative splicing or shedding) binds the TLR4/MD-2 co-receptor on monocytes to induce IDO, IL-10, and PGE2 in an IRAK-1 degradation–COX-2–dependent manner that suppresses T cell proliferation, while CD83 mRNA export from nucleus to cytoplasm is regulated by a HuR/APRIL/CRM1-dependent pathway via a coding-region post-transcriptional regulatory element, and its protein is subject to ubiquitin-mediated proteasomal degradation by the E3 ligase GRAIL at cytoplasmic lysines K168/K183 and to glycosylation-dependent trafficking via interaction with GRASP55 through its C-terminal TELV motif.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD83 is a type I transmembrane immunoglobulin-superfamily glycoprotein that acts as a central rheostat of antigen-presenting cell function and T cell tolerance, operating through both membrane-bound and soluble forms [#10, #18]. Its membrane-bound form stabilizes surface MHC class II and CD86 by opposing E3 ubiquitin ligase-mediated turnover: the CD83 transmembrane domain blocks IL-10-driven MARCH1-mediated ubiquitination and degradation of these molecules in dendritic cells [#10], and CD83 acts genetically upstream of MARCH8 in thymic epithelial cells, where deletion of March8 rescues the impaired CD4+ T cell selection of CD83 transmembrane mutants [#11]. This stromal/thymic CD83 function is required for CD4+ single-positive thymocyte development, since the requirement maps to the thymic environment rather than the thymocytes themselves [#1], and CD83 likewise sustains surface MHC class II on peripheral B cells and DCs by limiting its internalization [#15]. Beyond antigen presentation, CD83 is cell-intrinsically required across multiple immune lineages — in B cells for germinal center composition and antibody responses [#22], in regulatory T cells for differentiation and resolution of inflammation [#23], and in DCs, macrophages, and microglia as a restraint on pro-inflammatory activation, with conditional deletion aggravating EAE, colitis, and autoimmunity while enhancing bacterial clearance [#19, #24, #25, #26]. Membrane CD83 also functions in the immunological synapse, enhancing intracellular calcium release in interacting T cells [#31] and transducing an inhibitory homotypic signal through suppression of p38\\u03b1 phosphorylation [#19]. The soluble form (generated by shedding and by alternative splicing) is immunosuppressive [#4, #5]: it binds the TLR4 co-receptor MD-2 on CD14+ monocytes, triggering IRAK-1 degradation and COX-2\\u2013dependent induction of IDO, IL-10, and PGE2 that suppress T cell proliferation [#17, #18], an IDO/TGF-\\u03b2 axis that resolves autoimmune arthritis and uveitis in vivo [#27, #28]. CD83 expression is controlled at the transcriptional level by an IRF/NF-\\u03baB ternary promoter complex driving maturation-specific induction [#14] and post-transcriptionally by a coding-region RNA element that, via HuR and APRIL/ANP32B, directs CRM1-dependent nuclear export of CD83 mRNA [#7, #8]; the protein is further regulated by GRAIL-mediated ubiquitination at cytoplasmic lysines K168/K183 [#12] and by GRASP55-dependent glycosylation and surface trafficking through its C-terminal TELV motif [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that CD83 surface expression depends on a specialized nucleocytoplasmic step, revealing that CD83 mRNA export is rate-limiting for protein production.\",\n      \"evidence\": \"Pharmacological block of eIF-5A hypusination (GC7) and analysis of CD83 mRNA export plus DC-mediated T cell activation\",\n      \"pmids\": [\"10790432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Indirect pharmacological mechanism\", \"cis-element and trans-factors not yet identified\", \"did not define the export receptor\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"First defined the soluble CD83 ectodomain as a functional inhibitor, showing CD83 binds a non-homophilic ligand on DCs and suppresses DC maturation and T cell proliferation.\",\n      \"evidence\": \"Recombinant hCD83ext binding and DC maturation / T cell proliferation assays in vitro\",\n      \"pmids\": [\"11748282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity not determined\", \"in vitro only\", \"molecular mechanism of inhibition unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Characterized CD83 as an adhesion receptor with a sialylated counterreceptor, and showed soluble CD83 is generated by shedding rather than new synthesis.\",\n      \"evidence\": \"CD83-Ig fusion binding, neuraminidase treatment, immunoprecipitation of a 72-kDa counterreceptor, and shedding analysis by ELISA/Western with synthesis inhibition\",\n      \"pmids\": [\"11238630\", \"11431426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"72-kDa counterreceptor not molecularly identified\", \"shedding protease unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated a non-redundant in vivo requirement for CD83 in thymic stroma for CD4+ T cell development, defining its developmental role.\",\n      \"evidence\": \"CD83-/- mice with reciprocal thymocyte/bone-marrow adoptive transfer and flow cytometry\",\n      \"pmids\": [\"11955430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism in TECs not defined at this stage\", \"did not connect to MHC II regulation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved how soluble CD83 arises and functions, identifying splice variants encoding soluble protein, disulfide dimerization at C129, and intracellular trafficking through Golgi/recycling endosomes.\",\n      \"evidence\": \"RT-PCR splice variant mapping with recombinant protein MLR assays; C129S mutagenesis; immunofluorescence colocalization with endocytosis and cathepsin inhibition\",\n      \"pmids\": [\"15905506\", \"15721284\", \"15746244\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative in vivo contribution of splicing vs shedding to sCD83 pool unclear\", \"trafficking machinery only partly defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the post-transcriptional control of CD83, identifying a coding-region RNA element bound by HuR and the cofactor APRIL/ANP32B that routes the mRNA through CRM1-dependent export.\",\n      \"evidence\": \"RNA-binding assays, reporter constructs, RNAi, leptomycin B, dominant-negative Nup214, and APRIL phosphosite mutagenesis\",\n      \"pmids\": [\"16484227\", \"17178712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of HuR-element recognition unresolved\", \"how this pathway is coupled to DC maturation signals unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established CD83 as an intrinsic enhancer of DC immunostimulatory capacity and a stabilizer of surface MHC class II on B cells and DCs.\",\n      \"evidence\": \"siRNA knockdown in monocyte-derived DCs with T cell proliferation/cytokine readouts; CD83-/- mice with MHC II surface vs intracellular and internalization assays\",\n      \"pmids\": [\"17442926\", \"17804692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking CD83 to reduced MHC II internalization not yet molecular\", \"no ligase identified at this point\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the E3 ligase GRAIL as a regulator of CD83 protein stability, mapping ubiquitination to cytoplasmic K168/K183 and linking CD83 to T cell costimulation.\",\n      \"evidence\": \"GRAIL transduction and domain/lysine mutagenesis, ubiquitination and proteasome assays, RNAi rescue, and CD4+ T cell activation assays\",\n      \"pmids\": [\"19542455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of GRAIL-CD83 axis not tested\", \"stoichiometry of degradation unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the dominant membrane mechanism by which CD83 sustains antigen presentation: its transmembrane domain antagonizes MARCH1-mediated ubiquitination of MHC II and CD86, while the soluble form was shown to act via monocyte COX-2/PGE2.\",\n      \"evidence\": \"ENU TM-domain mutant mice with MARCH1 ubiquitination and IL-10 assays; T cell assays with COX-2 inhibitor NS-398 and monocyte depletion/transwell\",\n      \"pmids\": [\"21220452\", \"22065790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the TM domain physically blocks MARCH1 unresolved\", \"molecular target of sCD83 on monocytes not yet identified in 2011\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Dissected CD83 transcriptional control and synapse signaling functions, defining an IRF/NF-\\u03baB promoter complex, a homotypic inhibitory signal via p38\\u03b1, and enhancement of T cell calcium release.\",\n      \"evidence\": \"ChIP/EMSA/reporter/mutagenesis of the CD83 promoter; conditional DC-CD83 KO colitis model with truncation mutants and p38 assays; siRNA/antibody blocking with calcium imaging\",\n      \"pmids\": [\"23339870\", \"25204675\", \"24436459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating homotypic signal unidentified\", \"link between calcium enhancement and downstream T cell fate unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended CD83's MARCH-antagonist role to thymic MARCH8 via genetic epistasis, and established a B cell-intrinsic requirement for activation and germinal center responses.\",\n      \"evidence\": \"March8/Cd83 double-mutant mice with TEC MHC II and T cell selection analysis; B cell-specific conditional KO with mixed bone marrow chimeras, GC and IgE analysis, Borrelia infection\",\n      \"pmids\": [\"27503069\", \"26983787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether membrane CD83 directly contacts MARCH ligases is not shown\", \"GC dark/light zone mechanism incompletely defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified GRASP55 as a direct CD83 partner controlling glycosylation and surface trafficking via the C-terminal TELV motif.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, TELV-motif mutagenesis with glycosylation and surface expression readouts\",\n      \"pmids\": [\"25701785\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab interaction without reciprocal in vivo validation\", \"how glycosylation state alters CD83 function unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the receptor for soluble CD83, showing it binds MD-2 within the TLR4/MD-2 complex on monocytes to drive IRAK-1 degradation and COX-2-dependent IDO/IL-10/PGE2.\",\n      \"evidence\": \"Binding assays identifying MD-2, IRAK-1 degradation, downstream mediator induction with COX-2 inhibition, and T cell assays\",\n      \"pmids\": [\"28193829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct structural sCD83-MD-2 interaction not solved\", \"whether membrane CD83 uses the same receptor unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established cell-intrinsic CD83 requirements in regulatory T cells and defined soluble CD83 tolerogenic mechanisms in autoimmunity through cytoskeletal/calcium synapse disruption.\",\n      \"evidence\": \"Treg-specific conditional KO with scRNA-seq and autoimmunity models; EAU model with sCD83 imaging of F-actin and calcium microdomains\",\n      \"pmids\": [\"29875316\", \"30050530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular sensor linking CD83 to Treg gene program unknown\", \"synapse-disruption mechanism single-lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined DC-intrinsic CD83 as a brake on T cell priming and supporter of Treg function, and the sCD83 IDO/TGF-\\u03b2 axis as a resolution pathway in arthritis.\",\n      \"evidence\": \"DC-specific conditional KO with bacterial infection and EAE models; AIA model with IDO inhibitor and anti-TGF-\\u03b2 blockade plus osteoclast/Treg readouts\",\n      \"pmids\": [\"31527313\", \"31001257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CD83 loss elevates DC IL-2/IL-12 mechanistically unresolved\", \"in vivo source of IDO-inducing sCD83 receptor not pinpointed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended CD83's anti-inflammatory checkpoint role to tissue macrophages and microglia, showing it sustains alternatively activated/pro-resolving phenotypes.\",\n      \"evidence\": \"Macrophage- and microglia-specific conditional KO with STAT-6/receptor/cytokine and phagocytosis readouts, wound healing, scRNA-seq, and EAE\",\n      \"pmids\": [\"36875129\", \"37528070\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CD83 acts membrane-intrinsically or via shedding in these cells unclear\", \"direct molecular effectors downstream of CD83 in myeloid cells undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the membrane CD83 receptor/ligand mediating its costimulatory, calcium, and homotypic signals, and the structural basis for its antagonism of MARCH ligases, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined membrane CD83 receptor despite multiple functional readouts\", \"no structure of CD83-MARCH or CD83-MD-2 complexes\", \"relative in vivo contribution of membrane vs soluble CD83 not partitioned\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [10, 11, 12]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [18, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 20]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [20, 21]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 10, 22, 24]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [10, 11, 12]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [18, 19, 31]}\n    ],\n    \"complexes\": [\"TLR4/MD-2 co-receptor complex (soluble CD83 binding partner)\"],\n    \"partners\": [\"MD-2\", \"MARCH1\", \"MARCH8\", \"RNF128\", \"ELAVL1\", \"ANP32B\", \"GORASP2\", \"CD86\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}